Here are three things to know:
1. The company raised gross proceeds of $16.2 million from a capital increase Dec. 13, which it will used to fund the phase 2 clinical study of its proprietary KUR-113 spinal fusion product and advance commercialization of MagnetOs.
2. The phase 2 study of KUR-113 will begin enrolling patients in second quarter 2019, with an anticipated interim readout by the second half of 2020.
3. Michael Grau joined Kuros as CFO and Pascal Longlade, MD, joined as CMO.
More articles on biologics:
3 things to know about Royal Biologics
FDA to crackdown on ‘bogus’ stem cell treatments in 2019
Axolotl Biologix launches new regenerative fluid syringe for orthopedic wound care: 3 details
